2015 Fiscal Year Final Research Report
The impact of bevacizumab on EGFR-TKI and anti-EGFR antibody
| Project/Area Number |
26893155
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-08-29 – 2016-03-31
|
| Keywords | 非小細胞肺癌 / EGFRT790M / アファチニブ / セツキシマブ / ベバシツズマブ |
|---|
| Outline of Final Research Achievements |
EGFR mutations is major oncogenic driver mutation in non-smoking related lung cancers. EGFR-TKI is standard therapy for the lung cancers, however acquired resistance is inevitable. Secondary acquired mutation, EGFR T790M is major cause of the resistance.This pre-clinical reserach focused on the effect of triplet therapy with EGFR-TKI(afatinib), anti-EGFR antibody(cetuximab) and anti VEGF antibody(bevacizumab). Lung adenocarcinoma cell lines harboring EGFR T790M, H1975 and RPC-9 cell lines were transplanted in nude mice for xenograft models. The effect of each monotherapies or double therapies were moderate in the mice models. In contrast, the triplet therapy recurrently induced complete remission in the mice models.
|
| Free Research Field |
呼吸器腫瘍
|
